Welcome to our dedicated page for Si-Bone SEC filings (Ticker: SIBN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The engineering detail behind Si-Bone’s iFuse implant systems is impressive—so are the disclosures that explain it. Yet deciphering how FDA clearances, clinical-trial updates, and reimbursement shifts flow through Si-Bone’s SEC filings can overwhelm even seasoned analysts. If you have ever skimmed a footnote searching for implant revenue or tried to locate surgeon adoption metrics, you know the pain.
Stock Titan eliminates that friction. Our AI-powered summaries translate dense 10-K language into plain English, flag the exact tables you need, and attach context from peer companies. Need Si-Bone insider trading Form 4 transactions or Si-Bone Form 4 insider transactions real-time? We alert you the moment they hit EDGAR. Looking for the latest Si-Bone quarterly earnings report 10-Q filing or a quick Si-Bone earnings report filing analysis? One click shows revenue by implant family, gross-margin trends, and cash-flow commentary—no scrolling required.
- 10-K: Get the Si-Bone annual report 10-K simplified with AI highlights on clinical research spending and IP protection.
- 10-Q: Compare quarter-over-quarter shipment volumes and reimbursement wins.
- 8-K: See Si-Bone 8-K material events explained, including FDA submissions or pivotal study read-outs.
- DEF 14A: Drill into the Si-Bone proxy statement executive compensation to understand how leadership incentives align with implant adoption.
Whether you’re monitoring Si-Bone executive stock transactions Form 4, modelling implant revenue, or simply understanding Si-Bone SEC documents with AI, our platform surfaces what matters. Real-time updates, clear commentary, and exportable data help investors act on insights rather than hunt for them.
SI-BONE, Inc. (SIBN) filed a Form 4 reporting stock sales by its Chief Financial Officer, Anshul Maheshwari. The CFO sold 1,200 shares of common stock on 11/21/2025 at a weighted-average price of about $20.0133 per share and an additional 100 shares on 11/25/2025 at $20.00 per share. These sales were made under a pre-arranged Rule 10b5-1 trading plan dated December 13, 2024, which is designed to allow insiders to sell stock according to a set schedule.
Following these transactions, Maheshwari beneficially owns 203,773 shares of SI-BONE common stock. This total includes 143,116 shares issuable upon settlement of restricted stock units, each representing a right to receive one share of common stock.
SI-BONE, Inc. (SIBN)11/17/2025, he sold 1,707 and 2,126 shares of common stock in two transactions at weighted average prices of $17.4232 and $17.4462, respectively. These sales were made to cover tax withholding obligations arising from the vesting of restricted stock units and are described as non-discretionary “sell to cover” trades.
Following these transactions, the reporting person beneficially owned 268,144 shares of SI-BONE common stock, including 133,316 shares issuable upon settlement of restricted stock units, with each unit representing a contingent right to receive one share.
SI-BONE, Inc. (SIBN) reported an insider transaction by its Senior Vice President, Operations & Administration and Chief Legal Officer on 11/17/2025. The executive sold 1,478 and 1,850 shares of common stock in two separate trades, coded as sales.
According to the disclosure, these sales were made solely to cover tax withholding obligations arising from the vesting of restricted stock units under a "sell to cover" arrangement and are described as non-discretionary trades. After the transactions, the reporting person beneficially owned 251,896 shares of common stock, including 125,823 shares issuable upon settlement of restricted stock units, each unit representing a right to receive one share.
SI-BONE, Inc. insider trading report: The Chief Financial Officer of SI-BONE, Inc. (SIBN) reported two sales of common stock on 11/17/2025 totaling 3,460 shares. One sale covered 1,275 shares at a weighted average price of $17.4098, and another covered 2,185 shares at a weighted average price of $17.4369. According to the disclosure, these transactions were "sell to cover" sales required to satisfy tax withholding obligations related to vesting restricted stock units and were not discretionary trades. After these transactions, the reporting person beneficially owned 205,073 shares of common stock, including 143,116 shares issuable upon settlement of restricted stock units.
SI-BONE, Inc. (SIBN)11/17/2025, she sold several small blocks of common stock, including 2,028 shares at a weighted average price of $17.4401, 2,231 shares at $17.4449, 3,197 shares at $17.4341, and 3,885 shares at $17.3996.
The filing explains that these sales were required to cover tax withholding obligations tied to the vesting of restricted stock units and were executed as "sell to cover" transactions rather than discretionary trades. On 11/18/2025, 5,411 additional shares were sold at a weighted average price of $17.6978 under a Rule 10b5-1 trading plan dated December 13, 2024.
After these transactions, Francis beneficially owned 408,363 shares directly, including 373,980 shares issuable upon settlement of restricted stock units, and 351,319 shares indirectly through a trust.
SI-BONE (SIBN) reported an insider transaction by CEO and Director Laura A. Francis. She sold 5,411 shares of common stock on 11/11/2025 at a weighted‑average price of $17.0591, effected under a Rule 10b5-1 trading plan dated December 13, 2024.
After the sale, 356,730 shares were held indirectly by a trust, and 419,704 shares were held directly. The direct figure includes 396,297 shares issuable upon settlement of restricted stock units.
SI-BONE (SIBN) director Jeffrey W. Dunn reported option exercises and related sales on 11/11/2025. He exercised stock options at $4.32 for 23,148 shares and 56,852 shares, then sold the same amounts at $18.95 per share pursuant to a Rule 10b5-1 trading plan dated May 7, 2025.
Following these transactions, he directly held 10,307 shares. He also had indirect ownership of 118,874 shares held by The Jeffrey W. Dunn Living Trust. The direct total includes 10,307 shares issuable upon settlement of restricted stock units, each representing one share of common stock. The option awards referenced vest in equal monthly installments over four years, subject to continued service.
SI-BONE (SIBN)
SI-BONE (SIBN) reported Q3 2025 results with strong top-line growth and improved profitability trends. Revenue was $48,656,000, up 20.6% from $40,340,000, driven largely by higher U.S. case volumes. Gross margin expanded to 79.8% from 79.1%, lifting gross profit to $38,846,000.
Operating expenses rose to $44,229,000, primarily from higher sales and marketing and general and administrative costs, resulting in a smaller operating loss of $5,383,000 versus $7,633,000 a year ago. Net loss narrowed to $4,566,000 compared with $6,575,000, and net loss per share improved to $0.11 from $0.16.
Liquidity remained solid with cash and cash equivalents of $26,487,000 and short-term investments of $119,257,000. Inventory increased to $35,727,000 to support demand. Long-term borrowings were $35,540,000. Shares outstanding were 43,391,254 as of November 4, 2025.
SI-BONE, Inc. (SIBN) announced board and governance updates. Director Daniel Wolf resigned from the Board on November 6, 2025, and the company stated his resignation was not due to any disagreement with the company or management. Following his departure, the Board size was reduced from nine to eight, and current director Thomas A. West was appointed to the Audit Committee.
SI-BONE and Mr. Wolf entered into a 12-month consulting agreement covering marketing, strategy, business development and other corporate matters. The agreement accelerates vesting of 8,675 restricted stock units granted to Mr. Wolf on June 5, 2025, making them fully vested as of November 6, 2025, and provides cash compensation at an hourly rate set in applicable statements of work. The company also furnished a press release announcing results for the quarter ended September 30, 2025 as Exhibit 99.1.
FAQ
What is the current stock price of Si-Bone (SIBN)?
What is the market cap of Si-Bone (SIBN)?
